LipoScience, a medical technology company, has postponed its $75m (€76.4m) initial public offering which would have been the first IPO in the US since the middle of August.

Merrill Lynch was lead manager of the offer on Nasdaq. The company was aiming to sell five million shares at between $14 and $16 each. Pricing was initially due to take place on September 19 and then delayed to September 23 before the offer was finally pulled.